Century Therapeutics, Inc. Proceeds from Lease Payment, Operating Activity
Century Therapeutics, Inc. (IPSC) reported Proceeds from Lease Payment, Operating Activity of -$1.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLeasePayments · last filed 2026-08-12
- Century Therapeutics, Inc. proceeds from lease payment, operating activity for the quarter ending 2026-06-30 was -$989.00K.
- Century Therapeutics, Inc. proceeds from lease payment, operating activity for the quarter ending 2026-03-31 was -$786.00K.
- Century Therapeutics, Inc. proceeds from lease payment, operating activity for the quarter ending 2025-12-31 was -$1.40M.
- Century Therapeutics, Inc. proceeds from lease payment, operating activity for the quarter ending 2025-09-30 was $1.28M, a 36.96% decline year-over-year.
- Century Therapeutics, Inc. proceeds from lease payment, operating activity for fiscal 2025 was -$4.98M.
- Century Therapeutics, Inc. proceeds from lease payment, operating activity for fiscal 2024 was -$3.37M, a 124.35% decline from fiscal 2023.
- Century Therapeutics, Inc. proceeds from lease payment, operating activity for fiscal 2023 was $13.82M.
- Century Therapeutics, Inc. proceeds from lease payment, operating activity for fiscal 2022 was -$5.26M, a 12924.39% decline from fiscal 2021.
| Period end | Proceeds from Lease Payment, Operating Activity 3 month | Proceeds from Lease Payment, Operating Activity 3 month as first filed | Proceeds from Lease Payment, Operating Activity 6 month | Proceeds from Lease Payment, Operating Activity 6 month as first filed | Proceeds from Lease Payment, Operating Activity 9 month | Proceeds from Lease Payment, Operating Activity 9 month as first filed | Proceeds from Lease Payment, Operating Activity 12 month | Proceeds from Lease Payment, Operating Activity 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$989.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.77M 10-Q · filed 2026-08-12 | -$3.17M derived: sum of 3 quarters · filed 2026-08-12 | -$1.90M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | -$786.00K 10-Q · filed 2026-05-13 | -$2.19M derived: sum of 2 quarters · filed 2026-05-13 | -$906.00K derived: sum of 3 quarters · filed 2026-05-13 | -$4.61M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$120.00K derived: sum of 2 quarters · filed 2026-03-12 | -$3.82M derived: sum of 3 quarters · filed 2026-08-12 | -$4.98M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.42M derived: sum of 2 quarters · filed 2026-08-12 | -$3.58M 10-Q · filed 2025-11-13 | -$4.34M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | -$3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$4.86M 10-Q · filed 2026-08-12 | -$5.62M derived: sum of 3 quarters · filed 2026-08-12 | -$3.60M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | -$1.15M 10-Q · filed 2026-05-13 | -$1.92M derived: sum of 2 quarters · filed 2026-05-13 | $109.00K derived: sum of 3 quarters · filed 2026-05-13 | -$2.33M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$766.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.26M derived: sum of 2 quarters · filed 2026-03-12 | -$1.18M derived: sum of 3 quarters · filed 2026-03-12 | -$3.37M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$413.00K derived: sum of 2 quarters · filed 2025-11-13 | -$2.60M 10-Q · filed 2025-11-13 | $2.60M 10-Q · filed 2024-11-05 | $11.19M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$4.63M 10-Q · filed 2025-08-14 | $1.31M 10-Q · filed 2024-08-08 | $9.16M derived: sum of 3 quarters · filed 2025-08-14 | $9.16M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | -$2.19M 10-Q · filed 2025-05-15 | $2.19M 10-Q · filed 2024-05-09 | $11.60M derived: sum of 2 quarters · filed 2025-05-15 | $11.60M derived: sum of 3 quarters · filed 2025-05-15 | $11.60M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $13.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $13.79M derived: sum of 2 quarters · filed 2025-03-19 | $13.79M derived: sum of 3 quarters · filed 2025-03-19 | $13.82M 10-K · filed 2025-03-19 | $9.43M 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $31.00K 10-Q · filed 2024-11-05 | -$11.45M 10-Q · filed 2023-11-09 | -$1.67M derived: sum of 4 quarters · filed 2024-11-05 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $31.00K 10-Q · filed 2024-08-08 | -$6.72M 10-Q · filed 2023-08-09 | -$1.67M derived: sum of 3 quarters · filed 2024-08-08 | -$2.75M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $31.00K 10-Q · filed 2024-05-09 | -$1.67M derived: sum of 2 quarters · filed 2024-05-09 | -$2.75M derived: sum of 3 quarters · filed 2024-05-09 | -$5.38M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$2.78M derived: sum of 2 quarters · filed 2024-03-14 | -$5.41M derived: sum of 3 quarters · filed 2024-03-14 | -$5.26M 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$3.71M derived: sum of 2 quarters · filed 2023-11-09 | -$3.56M 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | -$2.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$2.48M 10-Q · filed 2023-08-09 | -$2.48M 10-Q · filed 2022-08-11 | |||||
| 2022-03-31 | $152.00K 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | $41.00K 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |